Stockscreener 앱 받기
0.56
7.16%
0.0374
시간 외 거래:
.57
0.010
+1.79%
전일 마감가:
$0.5226
열려 있는:
$0.53
하루 거래량:
502.81K
Relative Volume:
0.43
시가총액:
$31.98M
수익:
-
순이익/손실:
$-39.35M
주가수익비율:
-0.1564
EPS:
-3.58
순현금흐름:
$-48.92M
1주 성능:
-5.56%
1개월 성능:
+4.01%
6개월 성능:
-84.86%
1년 성능:
+25.81%
1일 변동 폭
$0.525
$0.56
1주일 범위
$0.5221
$0.6341
52주 변동 폭
$0.363
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
명칭
Elevation Oncology Inc
전화
(716) 371-1125
주소
101 FEDERAL STREET, BOSTON
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
Elevation Oncology Inc 주식(ELEV)의 최신 뉴스
Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - Yahoo Finance
Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News
Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex
It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex
Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com
Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily
Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News
Lombard Odier Asset Management Europe Ltd Invests $2.51 Million in Elevance Health, Inc. (NYSE:ELV) - Defense World
FDA grants fast track designation for Elevation Oncology’s EO-3021 - Pharmaceutical Business Review
Pacer Advisors Inc. Decreases Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Distillate Capital Partners LLC Grows Position in Elevance Health, Inc. (NYSE:ELV) - MarketBeat
Study Underscores Importance of Medicaid Coverage for Pregnant Women - Healthcare Innovation
Elevai Labs shares tumble on pricing of new stock offering - The Business Journals
Elevance Health, Inc. (NYSE:ELV) Position Boosted by Magnetar Financial LLC - Defense World
Decoding Elevance Health's Options Activity: What's the Big Picture? - Benzinga
ELAB’s price-to-free cash flow ratio: What it means for investors - US Post News
Ratios in Focus: Analyzing Elevation Oncology Inc (ELEV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga
Investing in Elevation Oncology Inc (ELEV) might be a great opportunity, but the stock is a bit undervalued - US Post News
Baltic Fintech Eleving To Raise Up To €30M In IPO - Law360
FDA grants fast track to Elevation Oncology's cancer drug - Investing.com
Ensign Peak Advisors Inc Acquires 2,862 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering - GlobeNewswire
Elevation Oncology Gets FDA Fast-Track Designation for EO-3021 - MarketWatch
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - StockTitan
Eleving Group Targets $34 Million From Initial Public Offering - MarketWatch
Fidelis Capital Partners LLC Acquires 1,168 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
1832 Asset Management L.P. Sells 5,622 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Frank Rimerman Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevance Health, Inc. (NYSE:ELV) Stock Position Decreased by Sompo Asset Management Co. Ltd. - Defense World
Sound Shore Management Inc. CT Sells 32,574 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Callan Capital LLC Buys 391 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Blair William & Co. IL Has $8 Million Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevation Oncology faces Nasdaq delisting over low stock price - Investing.com
Bradley Foster & Sargent Inc. CT Sells 25 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevation Oncology faces Nasdaq delisting over low stock price By Investing.com - Investing.com Australia
Elevation Oncology Inc (ELEV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):